这是MYC向治疗的重要一步
Danielle F Atibalentja1, Anja Deutzmann1, Dean W Felsher2
1Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Trends in cancer
|April 5, 2024
概括
研究人员正在探索OMO-103,一种针对MYC原瘤基因的新疗法,这是许多癌症的关键驱动因素. 早期的临床试验显示,这种急需的癌症药物具有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 临床药理学 临床药理学
背景情况:
- MYC原瘤基因是一个重要的转录调节器,在人类癌症中经常发生变化.
- 开发有效的MYC向疗法仍然是瘤学药物开发的重大挑战.
- 针对MYC被认为是"圣杯",因为它在癌症进展中的核心作用.
研究的目的:
- 审查新型治疗剂OMO-103的第一阶段临床试验.
- 评估OMO-103在患有固体恶性瘤的患者中的安全性和耐受性.
- 为潜在的MYC向药物提供早期临床发现的概述.
主要方法:
- 第1阶段临床试验设计.
- 招募患有固体恶性瘤的患者.
- 管理和监测OMO-103的剂量和患者反应.
主要成果:
- 加拉尔达等人的报告. 详细介绍了第一阶段试验的结果.
- 提交了OMO-103最初的安全性和耐受性数据.
- 早期的疗效信号可能正在出现,需要进一步调查.
结论:
- OMO-103代表了一种潜在的新治疗策略,用于由MYC失调驱动的癌症.
- 第1期试验为未来的OMO-103.3临床开发提供了基础.
- 需要进一步的研究来证实MYC向疗法的疗效并扩大其使用范围.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K


